ArticleJournal for immunotherapy of cancer2016
TCR diversity - a universal cancer immunotherapy biomarker?
Article in Journal for immunotherapy of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Characterizing immune heterogeneity in gastric cancer by high-throughput T-cell receptor sequencing: predictive clonotypes and functional signatures.Translational cancer research · 2026Article
- TCR sequencing in cancer immunology and immunotherapy: what, when, where, why, and how.Journal for immunotherapy of cancer · 2026Review
- Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer.Journal for immunotherapy of cancer · 2025Article
- Article
- Cancer neoantigens as potential targets for immunotherapy.Clinical & experimental metastasis · 2022Review
- Immune infiltrate diversity confers a good prognosis in follicular lymphoma.Cancer immunology, immunotherapy : CII · 2021Article
- Partial recovery of disturbed V-J pairing profiles of T-cell receptor in people living with HIV receiving long-term antiretroviral therapy.Science China. Life sciences · 2021Article
- Review
- Analysis of the Heterogeneity of CD4Journal of immunology research · 2020Article
- Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.The Journal of pathology · 2020Article
- Association of the characteristics of B- and T-cell repertoires with papillary thyroid carcinoma.Oncology letters · 2018Article
- Cheating the Hunger Games; Mechanisms Controlling Clonal Diversity of CD8 Effector and Memory Populations.Frontiers in immunology · 2018Review
- Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors.Cancer management and research · 2018Review
- Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sipuleucel-T was approved as a treatment for men with advanced metastatic, castration-resistant prostate cancer on the basis of improved survival in randomized clinical trials. A major challenge for this therapy, as well as other newer cancer immunotherapy agents, has been to identify markers that can identify patients who benefit from these therapies. In a recent manuscript by Sheikh and colleagues, the investigators evaluated changes in T cell clonality in the peripheral blood and tumors of patients treated with sipuleucel-T using next generation sequencing of T cell receptor Vß CDR3 sequences. Their findings are discussed in the context of this trial and other cancer immunotherapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.